[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 2, 1974

Serogroup C Meningococcal Vaccine: Limited-Use License by FDA

Author Affiliations

Duke University Medical Center Durham, NC

JAMA. 1974;229(10):1287. doi:10.1001/jama.1974.03230480015018

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor.—  A vaccine prepared from serogroup C meningococcus has been licensed by the Food and Drug Administration (FDA) for limited use in adults who are at increased risk of meningococcal disease. As a result of this FDA action, the vaccine, which has been used for several years in US military basic-training camps, will now be available for use outside the United States. The FDA licensing, while not required for use by the Defense Department in US military personnel, is necessary for vaccine that is to be exported. In granting a limited-use license, the FDA has restricted the vaccine to adults that are at unusual risk of acquiring disease due to serogroup C meningococcus. Early